GeneOhm Sciences Canada, Inc. develops diagnostic tests for the detection and identification of bacterial infections, fungal, and parasite infections. The company is headquartered in Sainte-Foy, Canada.

Guangzhou Xinchuangyi Drug Clinical Research Co., Ltd., established on 2019-01-16, Business scope includes drug research and development;Pharmaceutical Research Services;Medical Research and Experimental Development;Natural science research and experimental development;Human Science Research,to develop;Health Sciences Program Research,to develop;Information Technology Consulting Services;

The Max Planck Society for the Advancement of Science (German: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.; abbreviated MPG) is a non-governmental and non-profit association of Research Institutes publicly funded by the federal and the state governments of Germany. Additionally, the Max Planck Society and its Institutes receive third party funding from public and private contributions and from the European Union. The world leading organization is named in honor of its former president, theoretical physicist Max Planck. The 86 Institutes and Research Facilities of the Max Planck Society (as of 2020) conduct basic research in the natural sciences, life sciences, social sciences, and the arts and humanities. They have a total staff of approximately 24,000 permanent employees, including 15,000 scientists, and around 5,000 non-tenured scientists and guests. As of December 31, 2018, the proportion of female employees was 44.4 percent. The Max Planck Society (with its 86 Max Planck Institutes) has a world-leading reputation as a science and technology research organization, with more than 33 Nobel Prizes awarded to its scientists, and is widely regarded as one of the foremost basic research organizations in the world.

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

ELITechGroup, Inc., part of ELITech Group SAS, is an American company located in Logan, UT, that manufactures vaporizer.

Melinta Therapeutics is an antibiotics-focused company. The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus.

Zhejiang Quark Biotechnology Co., Ltd., established on 1998-12-23, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class II Medical Devices;Medical equipment rental;Special Equipment Repair;Specialty Chemicals Sales(Free of Hazardous Chemicals);Disinfectant sales(Free of Hazardous Chemicals);Sales of hygiene products and single-use medical products;Production of Class I Medical Devices;Sales of Class I Medical Devices;Instrument sales;Manufacturing of special equipment(Manufacture of licensed professional equipment not included)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Disinfectant production(Free of Hazardous Chemicals);Production of hygiene products and single-use medical products;road freight transport(Does not contain dangerous goods);Import and export;Technology Import and Export;Animal Clinic;Inspection and testing service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Beijing Botai Weiming Biotechnology Co., Ltd., established on 2013-10-08, Business scope includes technology development,Technology Promotion,technical consulting,Technical Services,technology transfer;Sales of machinery and equipment,computer,Software and Auxiliary Equipment,Chemical Products(Does not contain dangerous chemicals and a class of precursor chemicals),stationery,electronic product;computer technology training;Natural science research and experimental development;Import and export,Technology Import and Export;sell food.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Sale of food and items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Jichi Medical University (自治医科大学 Jichi ika daigaku) is a private university in Shimotsuke, Tochigi, Japan, established in 1972. In 2008 the Gates Foundation awarded $100,000 to Hiroyuki Matsuoka, a medical researcher at the university, to do research on flying syringes.

Jingqianshan Technology (Beijing) Co., Ltd., established on 2021-09-29, Business scope includes technology development,technology transfer,technical consulting,Technical Services,Technology Promotion;software development;Sales of chemical products(No licensed chemical products),daily necessities,cosmetic,electronic product,household appliances,Office Supplies,Stationery,sporting goods,Equipment,hardware products,automobile parts,crafts,crop seeds(Packaged seeds no longer in packs only),fertilizer,Disinfectant,hygiene products,Instrumentation,Class I medical device,Class II medical device;Production of medical devices Class I;Import and export,Technology Import and Export,Agent import and export;Production of Class II Medical Devices;Production of Class III Medical Devices;food business;Class III medical device business.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Production of Class II Medical Devices;Production of Class III Medical Devices,food business,The operation of Class III medical devices and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

BioMerieux designs, develops, manufactures, and markets in vitro diagnostic systems for clinical and industrial applications. The company’s diagnostic systems consist of reagents and consumables used to conduct biological tests, for use in performing screening, diagnostic assistance, prognosis, and treatment monitoring; instruments, platforms, and autoanalyzers used for automated testing at high or low throughputs; software to process analyses and systems to interpret biological test results; and other related services such as the installation and maintenance of instruments, user training, and the audit of laboratory workflows. BioMerieux offers diagnostic systems for clinical applications including the diagnosis of infectious diseases, comprising HIV, tuberculosis, and respiratory diseases, as well as cardiovascular diseases and targeted cancers based on the analysis of biological samples such as blood, saliva, and urine; and for industrial applications including the analysis of microbiological manufacturing such as food, pharmaceuticals, and cosmetics. The company markets and sells its products through a network of distributors to private sector analysis laboratories, hospital laboratories, blood banks, and physician office laboratories; food, pharmaceutical, and cosmetics industries; and independent quality control laboratories. It has operations in Europe, the Middle East, Africa, North America, Asia-Pacific, and Latin America. BioMerieux were founded in 1963 and is headquartered in Marcy l’Etoile, France. It is a subsidiary of Institut Mérieux.

Zhongxiu Technology Co., Ltd., established on 2017-02-10, Business scope includes general items:Biochemical product technology research and development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;software development;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Manufacturing of electronic components;integrated circuit manufacturing;Disinfectant sales(Free of Hazardous Chemicals);Electrical Equipment Sales;Sales of labor protection products;Experimental analysis instrument sales;Chemical product sales(No licensed chemical products);Specialty Chemicals Sales(Free of Hazardous Chemicals);Electronic Components Retail;Wholesale of electronic components;Wholesale of computer software, hardware and auxiliary equipment;Sales of office equipment consumables;Office Supplies Sales;Daily necessities wholesale;Information Technology Consulting Services(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Technology Import and Export;Import and export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., established on 1993-01-30, The scope of business includes the manufacture of chemical pharmaceutical raw materials;Manufacturing of chemical preparations;Chinese patent medicine production;Manufacturing of Veterinary Drugs;Health food manufacturing;Packaging and decoration printing(branch only);

Jiangsu Aidea Pharmaceutical Co., Ltd. engages in the production, supply, research and development of UTI raw materials. The company operates through two segments: Formulated Products and Raw Materials. Its products include Folium Sennae Granules, Powdered Bacillus Tablets, Clindamycin Hydrochloride Capsules, Sodium Bicarbonate Tablets, Nitrendipine Tablets, Metronidazole Tablets, Compound Gentamycin Sulfate and Procaine Hydrochloride Sulfate Granules, Cefradine Capsules, Human Urinary Kallidinogenase, Crude Ulinastatin & Urokinase, High Purity Urokinase, Human Serum Albumin, Epidermal Growth Factor, Crude Human Epidermal Growth Factor, Beta-2 Microglobulin and Crude Beta-2 Microglobulin. Jiangsu Aidea Pharmaceutical was founded on December 15, 2009 and is headquartered in Yangzhou, China.

Henan Provincial Peoples Hospital is a private company headquartered in Zhengzhou, China, that operates as an hospital.

Vaxxilon AG, a subsidiary of Johnson & Johnson, is a company headquartered in Reinach, Switzerland. The firm develops and manufactures novel synthetic vaccines.\nThe company says this about itself: Vaxxilon, based in Reinach, Switzerland, is privately held by Idorsia Ltd, the Max Planck Society, and Seeberger Science. It was established in 2015 to discover and develop novel vaccines against major infectious diseases. The innovative technologies are based on the scientific insights and research of Professor Peter Seeberger of the Max Planck Institute of Colloids and Interfaces. Vaxxilon is advancing several vaccine candidates using homogeneous, rationally designed, synthetically produced carbohydrate antigens and novel carrier molecules.

Rempex Pharmaceuticals, Inc. is a San Diego-based pharmaceutical company focused on the discovery and development of new antibacterial drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens. The company’s internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance.

Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a company headquartered in Allschwil, Switzerland. The firm develops and commercializes pharmaceuticals. Jean-Paul Clozel is the current CEO, occupying that position since 2017.\nThe company says this about itself: Headquartered near Basel, Switzerland - a biotech-hub of Europe-Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of over 700 highly qualified specialists dedicated to realizing our ambitious targets, a fully functional research center, and a strong balance sheet – the ideal constellation to bringing R&D efforts to business success.